Drug Chatter -- Tracking biopharma stock chatter

Profile for Fate Therapeutics, Inc. (FATE)

« Back to company index

FATE Chatter Timeline

Stock Ticker for FATE

Most Active Tweeters for FATE

UserTweets
@Slambucket 11
@thejadedtrader 7
@JasonHolman5 7
@tribepublic 6
@TickerReport 6

Recent Tweets for FATE

techwhitepapers @techwhitepapers
@DrRaulCordoba thats what $FATE #fatetherapeutics w its IPSC platform intends to do no?
December 10th 2017, 11:12pm
techwhitepapers @techwhitepapers
$FATE changes this paradigm by putting the CAR-T cells ahead of the patients .. thus reducing time and complexity o… https://t.co/cbB9gK2dRt
December 10th 2017, 11:12pm
JasonHolman5 @JasonHolman5
Waiting on the $FATE ProTmune data, really hoping to see an improvement upon interim data but the seeming pivot of focus isn’t encouraging.
December 10th 2017, 1:12pm
stocknewstimes @stocknewstimes
Fate Therapeutics, Inc. $FATE Given Average Rating of “Buy” by Analysts https://t.co/k0QiUset8h
December 10th 2017, 7:12am
SleekMoneycom @SleekMoneycom
Fate Therapeutics, Inc. $FATE Given Average Rating of “Buy” by Analysts https://t.co/eTch0Vq1NY
December 10th 2017, 7:12am
intercooleronli @intercooleronli
Fate Therapeutics, Inc. $FATE Given Average Rating of “Buy” by Analysts https://t.co/N0N1xVCl51
December 10th 2017, 2:12am
TickerReport @TickerReport
Fate Therapeutics, Inc. $FATE Given Average Rating of “Buy” by Analysts https://t.co/hcfMCzObtx
December 10th 2017, 2:12am
TickerReport @TickerReport
Fate Therapeutics, Inc. $FATE Given Average Rating of “Buy” by Analysts https://t.co/01yF2c8HZM
December 10th 2017, 2:12am
ConsumerFeed @ConsumerFeed
Fate Therapeutics, Inc. $FATE Given Average Rating of “Buy” by Analysts https://t.co/8TNKPhRpFG #acn
December 10th 2017, 1:12am
CFinancialNews @CFinancialNews
Fate Therapeutics, Inc. $FATE Given Average Rating of “Buy” by Analysts https://t.co/BVcaM2D9Wq
December 10th 2017, 1:12am
AmericanBanking @AmericanBanking
Fate Therapeutics, Inc. $FATE Given Average Rating of “Buy” by Analysts https://t.co/69oODff88G
December 10th 2017, 1:12am
emq_news @emq_news
Fate Therapeutics, Inc. $FATE Given Average Rating of “Buy” by Analysts https://t.co/FrTP3UjjSc
December 10th 2017, 1:12am
Aenoreth @Aenoreth
RT @odibro: $FATE Announces Generation of CAR-targeted, TCR-null CD8??+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off…
December 9th 2017, 9:12pm
traderzjourney @traderzjourney
RT @mavericneo: $FATE #ASH17 Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8??+ T Cells from Clonal Engineered Master…
December 9th 2017, 7:12pm
mavericneo @mavericneo
$FATE #ASH17 Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8??+ T Cells from Clonal Engineered… https://t.co/XzGKmzw1rW
December 9th 2017, 6:12pm
sesiegler @sesiegler
RT @JasonHolman5: Of particular interest now is when $FATE begins openly discussing intentions of the subsidiary they created, Tfinity, to…
December 9th 2017, 6:12pm
JasonHolman5 @JasonHolman5
Of particular interest now is when $FATE begins openly discussing intentions of the subsidiary they created, Tfinit… https://t.co/vY3L79MwfO
December 9th 2017, 6:12pm
MogulAzam @MogulAzam
RT @Slambucket: $FATE Just released: Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8aß+ T Cells from Clonal Engineered…
December 9th 2017, 4:12pm
dailymailtimes @dailymailtimes
Fate Therapeutics $FATE Given Daily Media Impact Rating of 0.20 https://t.co/YcVyxXqc2T
December 9th 2017, 4:12pm
WKRBNews @WKRBNews
Fate Therapeutics $FATE Given Daily Media Impact Rating of 0.20 https://t.co/NbEYHfWF07
December 9th 2017, 4:12pm
dailypoliticaln @dailypoliticaln
Fate Therapeutics $FATE Given Daily Media Impact Rating of 0.20 https://t.co/Mm78KPQzfe
December 9th 2017, 3:12pm
midetimes @midetimes
Fate Therapeutics $FATE Given Daily Media Impact Rating of 0.20 https://t.co/nSo5WIDo7S
December 9th 2017, 3:12pm
thejadedtrader @thejadedtrader
$FATE Fate Therapeutics holds an exclusive license to the intellectual property covering the CAR constructs, addin… https://t.co/931BHtmBhR
December 9th 2017, 3:12pm
thejadedtrader @thejadedtrader
$FATE The platform is supported by an IP portfolio of more than 90 issued patents and 100 pending patent applicati… https://t.co/uMc1Ls480W
December 9th 2017, 3:12pm
thejadedtrader @thejadedtrader
$FATE https://t.co/mmkuJ2B243
December 9th 2017, 3:12pm
SeattleTechie40 @SeattleTechie40
RT @JasonHolman5: https://t.co/YLHbJ6KMHg $FATE presents their CRISPR modified iPSCs for off the shelf CAR-T at ASH; 1st Candidate CD19(pr…
December 9th 2017, 3:12pm
hotpennyalerts @hotpennyalerts
$FATE - Clonally-derived CAR T Cells Display TRAC-regulated CAR Expression, Antigen Specificity, Anti-tumor Potency https://t.co/gjMkcRAjTA
December 9th 2017, 2:12pm
n_yigitbasi @n_yigitbasi
$FATE Announces Generation of CAR-targeted, TCR-null CD8??+ T Cells from Clonal Engineered Master Pluripotent Cell… https://t.co/HVm3oonrYf
December 9th 2017, 2:12pm
techwhitepapers @techwhitepapers
$FATE is developing a true off the shelf CAR-T cell therapy platform .. the follower has the chance to become the leader?
December 9th 2017, 1:12pm
BiotechFun @BiotechFun
@dhovekamp42 Why now? Cant wait till monday AM for algos to wake up? $fate
December 9th 2017, 1:12pm
JasonHolman5 @JasonHolman5
https://t.co/YLHbJ6KMHg $FATE presents their CRISPR modified iPSCs for off the shelf CAR-T at ASH; 1st Candidate C… https://t.co/hrRZV4cRKo
December 9th 2017, 1:12pm
dhovekamp42 @dhovekamp42
$FATE https://t.co/84VcGwAIxt https://t.co/6hNdxcORne
December 9th 2017, 1:12pm
Slambucket @Slambucket
$FATE Just released: Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8aß+ T Cells from Clonal En… https://t.co/dvUNuHfsPN
December 9th 2017, 12:12pm
stockboardinc @stockboardinc
$FATE Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8?? T Cells from Clonal Engin... - https://t.co/TNuAzHVm72
December 9th 2017, 12:12pm
livetraderalrt @livetraderalrt
$FATE Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8??+ T Cells from Clonal Engineered Master… https://t.co/M708lUxN1C
December 9th 2017, 12:12pm
odibro @odibro
$FATE Announces Generation of CAR-targeted, TCR-null CD8??+ T Cells from Clonal Engineered Master Pluripotent Cell… https://t.co/XRVjS4VgTu
December 9th 2017, 12:12pm
GNWLive @GNWLive
Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8??+ T Cells from Clonal Engineered $FATE https://t.co/vU0Rg1zTUW
December 9th 2017, 12:12pm
VistaPResearch @VistaPResearch
RT @tribepublic: $FATE Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR N…
December 9th 2017, 1:12am
VistaPResearch @VistaPResearch
RT @tribepublic: $FATE Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer. http…
December 9th 2017, 1:12am
pennyomegaCRWE @pennyomegaCRWE
First Subject Treated with $FATE 's FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer https://t.co/SuJjGhdjXm
December 8th 2017, 8:12pm
nightowl000 @nightowl000
$FATE @techwhitepapers Great job being early strong advocate for $FATE super science! ... Among several other stock… https://t.co/ay0EIWyLyb
December 8th 2017, 7:12pm
JasonHolman5 @JasonHolman5
https://t.co/L7iueVM1rX.… $FATE 2nd of 3 FATE-NK100 trials (APOLLO in ovarian cancer) treated its first patient. Po… https://t.co/5UL7uKkHVu
December 8th 2017, 6:12pm
Slambucket @Slambucket
$FATE I believe FATE released this news on a Friday afternoon because they don't want it to get lost in the excitem… https://t.co/woaFuGshPE
December 8th 2017, 6:12pm
Briefingcom @Briefingcom
$FATE: Fate Therapeutics treats first subject with FATE-NK100 in APOLLO study for recurrent ovarian cancer https://t.co/l7Jcz9ruqg
December 8th 2017, 6:12pm
StockNewsNow @StockNewsNow
$FATE Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer https://t.co/tm3DPs0JWy
December 8th 2017, 5:12pm
BatScientist @BatScientist
$FATE Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent O...… https://t.co/RirwF5WSvW
December 8th 2017, 4:12pm
IncredibleTrade @IncredibleTrade
$FATE Fate Therapeutics (FATE) Reports First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer
December 8th 2017, 4:12pm
tribepublic @tribepublic
$FATE Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cance… https://t.co/vHTkQJBKkj
December 8th 2017, 4:12pm
NewsToDesk @NewsToDesk
$FATE: Early-stage study underway of Fate Therapeutics’ FATE-NK100: https://t.co/SW1qeIUACj
December 8th 2017, 4:12pm
SEEKINGALPHA_FS @SEEKINGALPHA_FS
Dosing underway in early-stage study of Fate Therapeutics' FATE-NK100 https://t.co/gZjxGXQhRb $FATE
December 8th 2017, 4:12pm

Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.